Q1 25 results: transition towards a new platform
For the three months to 31 December 24 (Q1 25) Benchmark Holdings reported a 30%YoY decline in revenue to £17.7m (currency adjusted, -25%YoY) arising from a 16%YoY decline in the contribution from Advanced Nutrition to £16.1m, and £1.6m from Health operations. The Q1 (adj.) EBITDA loss was £(0.2)m (Q1 24 £3.5m profit on a like-for-like basis). The Group expects regulatory approval leading to completion of the disposal (for an aggregate £260m) of the Genetics business by the end of March and subsequently plans a separate announcement on use of proceeds and plans for the restructured business.- Advanced Nutrition registered strong performance in its Mediterranean markets offset by continued weak demand for shrimp and an Artemia harvest affected by lower hatching rates. The business segment contributed £0.84m in (adj.) EBITDA compared to £4.6m in Q1 24 (-90%YoY), with gross profitability adversely impacted by a change in product mix.
- Health reflected the decision to cease mobile wellboat-based Ectosan®Vet and Clean Treat® operations, to be replaced by a combined onshore and client-focused approach. Demand for Salmosan®Vet sea lice treatment in Norway and Chile remained strong resulting in (adj.) EBITDA of £0.33m compared to £0.57m a year earlier. This partially offset the impact of the absence of wellboat-based revenues.
As the Group will update separately on completion of the disposal process, retirement of debt, decision on return of proceeds to investors, composition of the balance sheet and any further strategic or restructuring initiatives, we have suspended outlook and our Fair Value estimate. It is expected that the disposal process will conclude by the end of March.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.